Corterve
10 Studies Recruiting

Clinical Trials Near Kansas City, MO

Find research studies actively recruiting participants near Kansas City. Studies are run at established research institutions including University of Kansas Health System and Saint Luke's Health.

Top Research Institutions in Kansas City

1

University of Kansas Health System

2

Saint Luke's Health

Recruiting Studies Near Kansas City

#1

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

RECRUITINGPHASE4Takeda

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks. Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.

📍 Dothan, Alabama📍 Sun City, Arizona📍 Los Angeles, California
#2

Registry Study for Radiation Therapy Outcomes

RECRUITINGNot SpecifiedProton Collaborative Group

The purpose of this research study is to collect and analyze information from patients being treated with various forms of radiation therapy.

📍 Scottsdale, Arizona📍 Little Rock, Arkansas📍 San Diego, California
#3

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

RECRUITINGPHASE4American Thrombosis and Hemostasis Network

Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.

📍 Little Rock, Arkansas📍 Los Angeles, California📍 Sacramento, California
#4

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

RECRUITINGPHASE3National Cancer Institute (NCI)

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.

📍 Birmingham, Alabama📍 Mobile, Alabama📍 Anchorage, Alaska
#5

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

RECRUITINGPHASE2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).

📍 Birmingham, Alabama📍 Los Angeles, California📍 Sacramento, California
#6

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

RECRUITINGPHASE2ECOG-ACRIN Cancer Research Group

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if radiation therapy is more effective with or without cisplatin in treating patients with squamous cell carcinoma of the head and neck.

📍 Anchorage, Alaska📍 Anchorage, Alaska📍 Anchorage, Alaska
#7

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

RECRUITINGNAAbbott Medical Devices

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

📍 Phoenix, Arizona📍 Little Rock, Arkansas📍 Sacramento, California
#8

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

RECRUITINGPHASE3Amgen

This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

📍 Birmingham, Alabama📍 Dothan, Alabama📍 Fairhope, Alabama
#9

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

RECRUITINGPHASE2VA Office of Research and Development

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis

📍 Aurora, Colorado📍 West Haven, Connecticut📍 Gainesville, Florida
#10

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

RECRUITINGPHASE3Colorado Prevention Center

Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

📍 Fairhope, Alabama📍 El Centro, California📍 Sacramento, California

Clinical Trials in Kansas City: FAQ

How do I find clinical trials near Kansas City?

Corterve aggregates all actively recruiting clinical trials near Kansas City, MO from the ClinicalTrials.gov database. Simply browse the listings on this page or take our free health assessment to find trials you may qualify for.

Are clinical trials in Kansas City free?

Yes, clinical trials are free for participants. The research sponsor covers all study-related costs. Many trials near Kansas City, MO also provide compensation for your time and travel expenses.

What research institutions are located in Kansas City?

Kansas City is home to several leading research institutions, including University of Kansas Health System, Saint Luke's Health. These facilities run clinical trials across Oncology, Neurology, Cardiology, and other therapeutic areas.

Ready to Find a Trial Near You?

Take our free 2-minute health assessment to see research studies recruiting near Kansas City that you may be eligible for. No insurance required.

Start Free Assessment